Mr. Snyder has been at MolecularMD since its inception in 2006, where he served as Head of Sales and Marketing. In 2009, he acted as President and COO, directing strategic planning and organizational growth, and assumed the role of President and CEO in 2014.
MolecularMD is a molecular diagnostics company that develops, validates, and deploys a broad range of molecular diagnostic test offerings intended to support the regulatory approval and commercialization of precision medicines. In late 2017, MolecularMD received FDA authorization of their MRDx Test, an in vitro diagnostic indicated for managing treatment discontinuation for CML patients treated with nilotinib. MolecularMD is a diagnostic partner with top 20 oncology biopharma as well as with major platform and technology providers.
With more than 25 years of experience in the life science research and diagnostic fields, Mr. Snyder has led several venture backed organizations, accelerating growth by driving rapid market adoption for novel proteomic and genomic technologies.
Collaborating With the FDA: What Has Worked and What Hasn't?
2:20 PM - 3:10 PM